View Older Stories View More Recent Stories
-
Piper Sandler: 'We Would be Buyers of DOCS and PHR Following Pharma Marketing KOL Lunch'
-
Piper: 'We Would be Buyers of DOCS and PHR Following Pharma Marketing KOL Lunch in Boston'
-
Phreesia Inc. (PHR) PT Lowered to $25 at Raymond James
-
Phreesia Inc. (PHR) PT Lowered to $28 at Mizuho
-
Phreesia (PHR) Delivered Better than Expected F3Q26 Results - DA Davidson
-
Phreesia Inc. (PHR) PT Lowered to $33 at Canaccord Genuity
-
Phreesia (PHR) Has a Strong Market Position, is a Leading Brand - Citizens
-
Phreesia Inc. (PHR) Tops Q3 EPS by 7c, Beats on Revenue; Offers FY26 Revenue Guidance
-
Phreesia Inc. (PHR) PT Raised to $35 at DA Davidson
-
Phreesia Inc. (PHR) PT Raised to $36 at Truist Securities
-
Phreesia Inc. (PHR) PT Raised to $34 at Citizens JMP
-
Truist Securities Reiterates Sell Rating on Phreesia Inc. (PHR)
-
Phreesia Inc. (PHR) PT Raised to $33 at Raymond James
-
DA Davidson Assumes Phreesia Inc. (PHR) at Buy
-
Phreesia Inc. (PHR) PT Raised to $38 at Canaccord Genuity
-
Phreesia Inc. (PHR) PT Raised to $35 at Needham
-
Phreesia Inc. (PHR) Tops Q2 EPS by 7c, provides guidance
-
Phreesia launches VoiceAI to handle patient calls with conversational AI
-
Mizuho Starts Phreesia Inc. (PHR) at Outperform
-
KeyBanc on Phreesia Inc. (PHR): 'See Multiple Growth Catalysts for GARP-y'
-
Phreesia partners with Sesame Workshop for 5-year pediatric health initiative
-
JPMorgan Reiterates Overweight Rating on Phreesia Inc. (PHR)
-
DA Davidson Reiterates Buy Rating on Phreesia Inc. (PHR)
-
Phreesia Inc. (PHR) PT Lowered to $34 at Canaccord Genuity
-
Raymond James Reiterates Outperform Rating on Phreesia Inc. (PHR)
-
Piper Sandler Reiterates Overweight Rating on Phreesia Inc. (PHR) Following EPS
-
JPMorgan on Phreesia Inc. (PHR): 'Net/net we view this as a solid quarter'
-
Phreesia Inc. (PHR) PT Lowered to $33 at Citi
-
Citi Reiterates Buy Rating on Phreesia Inc. (PHR)
-
Phreesia Inc. (PHR) Tops Q1 EPS by 5c ; Offers Guidance
-
B2B marketplaces' longer adoption window support higher prices: Citizen's JMP
-
Phreesia Inc. (PHR) PT Raised to $32 at Jefferies
-
KeyBanc on Phreesia Inc. (PHR): 'Margin Ramp on Display to Achieve "Rule of 30"'
-
Raymond James Reiterates Outperform Rating on Phreesia Inc. (PHR)
-
DA Davidson Reiterates Buy Rating on Phreesia Inc. (PHR)
-
Phreesia Inc. (PHR) PT Raised to $35 at Canaccord Genuity
-
Phreesia Inc. (PHR) Tops Q4 EPS by 4c ; Offers Guidance
-
Truist Securities Reiterates Buy Rating on Phreesia Inc. (PHR)
-
Phreesia Inc. (PHR) PT Raised to $33 at Piper Sandler as 'Internal Investments Start To Pay Off'
-
RBC Capital Upgrades Phreesia Inc. (PHR) to Outperform
-
Phreesia Inc. (PHR) PT Lowered to $30 at Baird
-
Phreesia Inc. (PHR) Tops Q3 EPS by 2c, provides guidance
-
DA Davidson Reiterates Buy Rating on Phreesia Inc. (PHR)
-
Phreesia Inc. (PHR) PT Raised to $34 at Baird
-
Phreesia Inc. (PHR) PT Raised to $31 at Truist Securities
-
Piper Sandler Reiterates Overweight Rating on Phreesia Inc. (PHR)
-
Canaccord Genuity Reiterates Buy Rating on Phreesia Inc. (PHR)
-
Needham Reiterates Buy Rating on Phreesia Inc. (PHR)
-
Phreesia Inc. (PHR) Tops Q2 EPS by 4c, maintains guidance
-
Phreesia Inc. (PHR) Appoints Bob Glazer as Strategic Advisor

